Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics (LCTX) announced updated interim results from its Phase 1/2a study of OpRegen®, a cell therapy targeting dry age-related macular degeneration (AMD). The therapy aims to improve vision in patients with geographic atrophy. A podium presentation is scheduled for September 30, 2021, at the 54th Annual Scientific Meeting of the Retina Society in Chicago. The study includes a total of 24 patients, and the upcoming interim results will provide follow-up data for all treated patients, particularly focusing on Cohort 4, which showed better baseline vision.
Lineage Cell Therapeutics has appointed George A. Samuel III as its new General Counsel and Corporate Secretary. With nearly 15 years in corporate and transactional law, his background includes roles at Lytx and Cardiff Oncology, where he handled legal operations and compliance. The company anticipates Samuel's expertise will support its clinical development efforts and business partnerships, particularly for its OpRegen, OPC1, and VAC2 programs, which target significant medical needs and market opportunities.
Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 2021 results, highlighting significant advancements in its clinical programs, particularly OpRegen for dry-AMD. Notably, 83% of patients exhibited stable or improved visual acuity six months post-treatment. The company is also reacquiring OPC1 for clinical trials, aided by a robust cash position of $68.7 million. Total revenue increased to $0.5 million due to new licensing agreements, despite a net loss of $4.8 million. Lineage's inclusion in the Russell 3000® Index is expected to enhance visibility.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the H.C. Wainwright & Co. Inc. Virtual Ophthalmology Conference on August 17, 2021. The presentation will be available on-demand starting at 7am ET, and Mr. Culley will also join a panel discussion on addressing unmet medical needs in macular degeneration at 11am ET. Interested viewers can register for these presentations on the company's website, which also offers additional media resources.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) will release its second quarter 2021 financial and operating results on August 12, 2021. Following market closure, management will host a conference call at 4:30 p.m. ET to discuss the results and offer a business update. Interested individuals can join by phone or access a live webcast on Lineage's investor relations page. Lineage is focused on developing allogeneic cell therapies for unmet medical needs, with three key product candidates in various stages of clinical development targeting significant markets.
Lineage Cell Therapeutics (LCTX) has reported promising interim results from its ongoing Phase 1/2a clinical study of OpRegen, aimed at treating dry age-related macular degeneration (AMD). In Cohort 4, 83% of treated eyes maintained or improved visual acuity, with gains reaching +19 letters on the ETDRS chart. Treatments indicated anatomical restoration and durability, with some patients showing no progression of geographic atrophy for almost three years. The company plans to discuss future clinical development steps with the FDA later this year, positioning OpRegen as a leading option for AMD treatment.
Lineage Cell Therapeutics, Inc. (LCTX) announced updated interim results from a Phase 1/2a study of its candidate, OpRegen®, targeting dry age-related macular degeneration (AMD). The study involved 24 patients and aimed to evaluate OpRegen's safety and tolerability, alongside preliminary efficacy. Results will be presented at the 54th Annual Scientific Meeting of the Retina Society in Chicago on September 30, 2021. OpRegen offers a thaw-and-inject formulation, simplifying administration. Currently, no FDA-approved treatments exist for atrophic AMD, emphasizing the significance of this development.
Lineage Cell Therapeutics (LCTX) has been added to the Russell 3000® and Russell Microcap® Indexes, effective today. This inclusion is a recognition of Lineage's progress in the field of cell therapy and regenerative medicine, with CEO Brian M. Culley emphasizing growth opportunities that could enhance investor awareness and liquidity. The Russell indexes capture the largest U.S. stocks based on market capitalization, affecting $10.6 trillion in assets. Lineage's diverse clinical pipeline includes therapies for dry age-related macular degeneration, spinal cord injuries, and lung cancer.
Lineage Cell Therapeutics (NYSE American: LCTX) announced progress on its OPC1 therapy for spinal cord injury (SCI). Following recent FDA feedback, the company plans to submit an IND amendment for a Phase 1 study utilizing Neurgain Technologies' delivery system. This study aims to evaluate the safety and efficacy of OPC1, with expectations to initiate a late-stage trial in 2022. Improvements in OPC1 cell production have been noted, and broader patient eligibility is anticipated. The Neurgain delivery system aims to enhance surgical precision without interrupting patients' breathing.
Lineage Cell Therapeutics (LCTX) has granted Amasa Therapeutics an exclusive option for a license to its HyStem technology aimed at treating solid tumors. This agreement includes an upfront cash payment, potential event-specific payments, and royalties on net sales if exercised. HyStem mimics the extracellular matrix, aiding in cell retention and viability for therapies targeting cancers like glioblastoma. This partnership enhances LCTX's position in oncology, while Amasa aims to expedite its clinical developments using HyStem's biomaterials.